Amlodipine

Generic Name: Amlodipine

Brand Names: Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₅ClN_₂O_₅

CAS Number: 88150-42-9

Unique Ingredient Identifier: 1J444QC288

Background: Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnorma...

Indication: Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :

• Hypertension

• Coronary artery disease

• Chronic stable angina

• Vasospastic angina (Prinzmetal’s or Variant angina)
...

Associated Conditions: Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Valsartan 320 mg
Drug: Amlodipine 10 mg
Drug: Hydrochlorothiazide

First Posted Date: 2005-09-15

Last Posted Date: 2011-06-06

Lead Sponsor: Novartis

Target Recruit Count: 125

Registration Number: NCT00171054

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia

Phase 4

Completed

Conditions: Hypertension
Hyperlipidemia

First Posted Date: 2005-09-15

Last Posted Date: 2021-01-27

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 330

Registration Number: NCT00174330

Locations: 🇨🇳
Pfizer Investigational Site, Tianjin, China

Amlodipine Diabetic Hypertension Efficacy Response Trial

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2005-09-12

Last Posted Date: 2021-01-28

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 739

Registration Number: NCT00159692

Double Blind Atorvastatin Amlodipine Study

Phase 4

Completed

Conditions: Angina

First Posted Date: 2005-09-12

Last Posted Date: 2021-01-28

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 360

Registration Number: NCT00159718

Locations: Pfizer Investigational Site

Effects of Amlodipine in the Management of Chronic Heart Failure

Phase 2

Terminated

Conditions: Chronic Heart Failure

First Posted Date: 2005-09-09

Last Posted Date: 2019-03-26

Lead Sponsor: Rennes University Hospital

Target Recruit Count: 7

Registration Number: NCT00151619

Locations: 🇫🇷
Service de Réanimation Médicale - Hôpital Raymond Poincaré, Garches, France
🇫🇷
Service de Réadaptation Cardio-Vasculaire - Clinique St Yves, Rennes, France

Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina

Phase 4

Completed

Conditions: Myocardial Ischemia

First Posted Date: 2005-09-02

Last Posted Date: 2021-01-28

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 200

Registration Number: NCT00143195

Locations: 🇬🇷
Pfizer Investigational Site, Zakynthos, Greece

Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance

Phase 4

Completed

Conditions: Hypertension
Type 2 Diabetes Mellitus

Interventions: Drug: Amlodipine
Drug: Valsartan

First Posted Date: 2005-08-11

Last Posted Date: 2013-05-01

Lead Sponsor: Nagoya University

Target Recruit Count: 1150

Registration Number: NCT00129233

Locations: 🇯🇵
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure

Phase 4

Completed

Conditions: Kidney Failure, Chronic

Interventions: Drug: Placebo
Drug: Amlodipine

First Posted Date: 2005-07-29

Last Posted Date: 2008-05-09

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 356

Registration Number: NCT00124969

Locations: 🇩🇪
Charite Campus Benjamin Franklin, Berlin, Germany

Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers

Phase 1

Completed

Conditions: Cardiovascular Diseases
HIV Infections
Hypertension

First Posted Date: 2002-06-20

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 32

Registration Number: NCT00039975

Locations: 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸
Cornell Univ Med Ctr, New York, New York, United States
🇺🇸
Univ of California San Francisco, San Francisco, California, United States

and more 6 locations

Genetics of Hypertension Associated Treatments (GenHAT)

Completed

Conditions: Hypertension
Heart Diseases
Coronary Disease
Myocardial Infarction
Cardiovascular Diseases

Interventions: Drug: Chlorthalidone
Drug: Lisinopril
Drug: Amlodipine
Drug: Doxazosin

First Posted Date: 2000-09-26

Last Posted Date: 2024-04-26

Lead Sponsor: Donna Arnett, 257-5678

Target Recruit Count: 37939

Registration Number: NCT00006294

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy